Key result
ORBITA trial establishes the design for evaluating PCI efficacy in stable angina.
RCT
Double-blind
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Surprisingly, even though the stents improved blood supply, they didn't provide more relief of symptoms compared to drug treatments, at least in this patient group.”
“The press release and the news article got it wrong by reporting a positive but non-statistically-significant change as zero or even negative. The research article got it right by saying 'there is no evidence'—actually, saying 'there is no strong evidence' would be a better way to put it, as the data do show some evidence for a difference.”
“It was impressive how negative it was.”
Randomized double-blind trial evaluates placebo-controlled efficacy of angioplasty in stable coronary disease, indicating significant implications for clinical practice and angina management.
Percutaneous coronary intervention (PCI) is widely believed to reduce angina in stable coronary artery disease but this has never been tested in a blinded randomised controlled trial. Such a study design exposed another highly credible therapy, renal denervation for hypertension, to be far less efficacious than unblinded evidence suggested. The results of Simplicity HTN3 study highlighted the placebo effects of interventional procedures, and there is increasing recognition for the need for placebo-controlled studies to investigate the effects of interventional therapies. The evidence for PCI in stable coronary artery disease in the reduction of myocardial infarction and mortality remains uncertain. The remit of coronary intervention in this setting may primarily be to offer symptom relief and improvement in quality of life. However, the clinical effects of PCI for these goals will be contributed to by both a true physical and a placebo component. The magnitude of the placebo-controlled effect of PCI on symptoms and exercise capacity has never been tested before. In order to scientifically address this question a double blind trial of coronary angioplasty versus a placebo procedure in patients with stable coronary artery disease was required. I designed, conducted and led the first placebo-controlled trial of PCI in stable coronary artery disease. In this thesis I will present the primary and secondary outcomes from the Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina (ORBITA) trial. I will also present the results of subsequent analyses stratifying the results of ORBITA by pre-randomisation invasive physiology using fractional flow reserve and instantaneous wave-free ratio and by pre-randomisation dobutamine stress echocardiography score. The results of this trial may have far-reaching consequences for the management of stable angina.
No takes yet. Share an insight, caveat, or question.
Al‐Lamee et al. (2017) conducted an RCT in Stable coronary artery disease. Percutaneous coronary intervention vs. Placebo procedure was evaluated. The abstract outlines the rationale for the ORBITA trial, a double-blind, placebo-controlled trial of percutaneous coronary intervention in stable angina, without reporting quantitative results.
Synapse has enriched 10 related papers. Consider them for comparative context: